{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:49:30Z","timestamp":1790304570227,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ART Viggo","award":["no number"],"award-info":[{"award-number":["no number"]}]},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie","award":["No number"],"award-info":[{"award-number":["No number"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to investigate risk factors for cutaneous adverse reactions (CARs) in Kinh Vietnamese.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients were prospectively recruited in Ho Chi Minh City. Presence of the HLA-B*58:01 allele was determined by real-time PCR-sequence-specific amplification by using the PG5801 Detection Kit (Pharmigene, Taipei). Patients with severe (SCARs) and mild (MCARs) CARs and controls were compared for differences in features prospectively collected, and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      On comparing 32 patients with SCARs and 395 tolerant controls, we identified eight strong risk factors: increased age (OR 15.1 [95% CI 5.8\u201340.1],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), female sex (OR 333 [40\u201343,453],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), allopurinol for asymptomatic hyperuricemia (OR 955 [120\u2013125,847],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), allopurinol starting dose &gt;\u2009150\u2009mg (OR 316 [101\u2013122],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), diuretics intake (OR 304 [35\u201340,018],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), eGFR &lt;\u200960\u2009ml\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      (OR 100 [32\u2013353],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), history of allopurinol-induced skin reaction (OR 78 [6\u201310,808],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004), and HLA-B*58:01 carriage (OR 147 [45\u2013746],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). HLA-B*58:01 allele frequency in controls was 7.3%. For MCARs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200974), risk factors were eGFR &lt;\u200960\u2009ml\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      (OR 4.9 [1.61\u201314.6],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006), history of allopurinol-induced skin reaction (OR 27 [2\u20133777],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01), and asymptomatic hyperuricemia (OR 27 [2\u20133777],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirmed 8 risk factors, including HLA-B*58:01, for SCARs and identified 3 risk factors for MCARs in Kinh Vietnamese. HLA-B*58:01 genotyping could guide the indication for allopurinol in Kinh Vietnamese patients with gout.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02273-1","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T09:02:04Z","timestamp":1598864524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study"],"prefix":"10.1186","volume":"22","author":[{"given":"Minh Duc","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao Phuong","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Duy","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang Dinh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghia Hieu","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh Gia Hoang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu Anh","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Ngoc","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Quoc","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Resche-Rigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-4790","authenticated-orcid":false,"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"issue":"10","key":"2273_CR1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, FitzGerald JD, Khanna PP, Bae S, Singh M, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part I: systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"2273_CR2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.semarthrit.2016.08.006","volume":"46","author":"SK Rai","year":"2017","unstructured":"Rai SK, Avi\u00f1a-Zubieta JA, McCormick N, De Vera MA, Shojania K, Sayre EC, et al. The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2017;46(4):451\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2273_CR3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","volume":"36","author":"SN Ramasamy","year":"2013","unstructured":"Ramasamy SN, Korb-Wells CS, Kannangara DRW, Smith MWH, Wang N, Roberts DM, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36(10):953\u201380.","journal-title":"Drug Saf"},{"issue":"9","key":"2273_CR4","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","volume":"175","author":"C-Y Yang","year":"2015","unstructured":"Yang C-Y, Chen C-H, Deng S-T, Huang C-S, Lin Y-J, Chen Y-J, et al. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 2015;175(9):1550\u20137.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2273_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","volume":"58","author":"S Halevy","year":"2008","unstructured":"Halevy S, Ghislain P-D, Mockenhaupt M, Fagot J-P, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2273_CR6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Newcomb C, Margolis D, Roy J, Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res. 2013;65(4):578\u201384.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2273_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.40.3.245","volume":"40","author":"GT McInnes","year":"1981","unstructured":"McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981;40(3):245\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"2273_CR8","first-page":"1217","volume":"316","author":"R Hoign\u00e9","year":"1987","unstructured":"Hoign\u00e9 R, Sonntag MR, Zoppi M, Hess T, Maibach R, Fritschy D. Occurrence of exanthems in relation to aminopenicillin preparations and allopurinol. N Engl J Med. 1987;316(19):1217.","journal-title":"N Engl J Med"},{"issue":"5","key":"2273_CR9","doi-asserted-by":"crossref","first-page":"e13316","DOI":"10.1111\/ijcp.13316","volume":"73","author":"C-W Lin","year":"2019","unstructured":"Lin C-W, Huang W-I, Chao P-H, Chen W-W, Hsiao F-Y. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: a nationwide study. Int J Clin Pract. 2019;73(5):e13316.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"2273_CR10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","volume":"12","author":"LK Stamp","year":"2016","unstructured":"Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016;12(4):235\u201342.","journal-title":"Nat Rev Rheumatol"},{"key":"2273_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335612","volume":"97","author":"M Mockenhaupt","year":"2012","unstructured":"Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1\u201317.","journal-title":"Chem Immunol Allergy"},{"issue":"2","key":"2273_CR12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2016.03.014","volume":"46","author":"N Lu","year":"2016","unstructured":"Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum. 2016;46(2):253\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"2273_CR13","first-page":"1187","volume":"77","author":"SF Keller","year":"2018","unstructured":"Keller SF, Lu N, Blumenthal KG, Rai SK, Yokose C, Choi JWJ, et al. Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Ann Rheum Dis. 2018;77(8):1187\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2273_CR14","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1468-3083.2011.04313.x","volume":"26","author":"L Atzori","year":"2012","unstructured":"Atzori L, Pinna AL, Mantovani L, Ferreli C, Pau M, Mulargia M, et al. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department--Cagliari University (Italy). J Eur Acad Dermatol Venereol. 2012;26(11):1424\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2273_CR15","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u201380.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2273_CR16","doi-asserted-by":"crossref","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","volume":"9","author":"S Saokaew","year":"2014","unstructured":"Saokaew S, Tassaneeyakul W, Maenthaisong R, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population. PLoS One. 2014;9(4):e94294.","journal-title":"PLoS One"},{"issue":"11","key":"2273_CR17","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","volume":"26","author":"J-W Jung","year":"2011","unstructured":"Jung J-W, Song W-J, Kim Y-S, Joo KW, Lee KW, Kim S-H, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011;26(11):3567\u201372.","journal-title":"Nephrol Dial Transplant"},{"key":"2273_CR18","first-page":"h4848","volume":"351","author":"T-M Ko","year":"2015","unstructured":"Ko T-M, Tsai C-Y, Chen S-Y, Chen K-S, Yu K-H, Chu C-S, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848.","journal-title":"BMJ."},{"issue":"4","key":"2273_CR19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/17425255.2017.1269745","volume":"13","author":"RO Day","year":"2017","unstructured":"Day RO, Kannangara DRW, Stocker SL, Carland JE, Williams KM, Graham GG. Allopurinol: insights from studies of dose-response relationships. Expert Opin Drug Metab Toxicol. 2017;13(4):449\u201362.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"2273_CR20","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","volume":"74","author":"W-H Chung","year":"2015","unstructured":"Chung W-H, Chang W-C, Stocker SL, Juo C-G, Graham GG, Lee M-HH, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2273_CR21","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529\u201336.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2273_CR22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FPC.0000000000000285","volume":"27","author":"N Saksit","year":"2017","unstructured":"Saksit N, Tassaneeyakul W, Nakkam N, Konyoung P, Khunarkornsiri U, Chumworathayi P, et al. Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics. 2017;27(7):255\u201363.","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"2273_CR23","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"S-I Hung","year":"2005","unstructured":"Hung S-I, Chung W-H, Liou L-B, Chu C-C, Lin M, Huang H-P, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2273_CR24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","volume":"13","author":"Z Cao","year":"2012","unstructured":"Cao Z, Wei Z, Zhu Q, Zhang J, Yang L, Qin S, et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics. 2012;13(10):1193\u2013201.","journal-title":"Pharmacogenomics."},{"issue":"9","key":"2273_CR25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","volume":"19","author":"W Tassaneeyakul","year":"2009","unstructured":"Tassaneeyakul W, Jantararoungtong T, Chen P, Lin P-Y, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704\u20139.","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"2273_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","volume":"21","author":"H-R Kang","year":"2011","unstructured":"Kang H-R, Jee YK, Kim Y-S, Lee CH, Jung J-W, Kim SH, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303\u20137.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"2273_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","volume":"13","author":"M Tohkin","year":"2013","unstructured":"Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13(1):60\u20139.","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"2273_CR28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99\u2013107.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"2273_CR29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","volume":"169","author":"M Gon\u00e7alo","year":"2013","unstructured":"Gon\u00e7alo M, Coutinho I, Teixeira V, Gameiro AR, Brites MM, Nunes R, et al. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol. 2013;169(3):660\u20135.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2273_CR30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/acr.22409","volume":"67","author":"D-J Park","year":"2015","unstructured":"Park D-J, Kang J-H, Lee J-W, Lee K-E, Wen L, Kim T-J, et al. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res. 2015;67(2):280\u20137.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"2273_CR31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","volume":"46","author":"E Jutkowitz","year":"2017","unstructured":"Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594\u2013600.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2273_CR32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/humu.23835","volume":"40","author":"VS Le","year":"2019","unstructured":"Le VS, Tran KT, Bui HTP, Le HTT, Nguyen CD, Do DH, et al. A Vietnamese human genetic variation database. Hum Mutat. 2019;40(10):1664\u201375.","journal-title":"Hum Mutat"},{"key":"2273_CR33","doi-asserted-by":"crossref","unstructured":"Do MD, Le LGH, Nguyen VT, Dang TN, Nguyen NH, Vu HA, et al. High-resolution HLA typing of HLA-A, -B, -C, -DRB1, and -DQB1 in Kinh Vietnamese by using next-generation sequencing. Front Genet. 2020;11 Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2020.00383\/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=510718. [cited 2020 May 4].","DOI":"10.3389\/fgene.2020.00383"},{"issue":"6","key":"2273_CR34","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","volume":"102","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6):28S\u201330S.","journal-title":"J Invest Dermatol."},{"issue":"D1","key":"2273_CR35","first-page":"D948","volume":"48","author":"J Robinson","year":"2020","unstructured":"Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT\/HLA database. Nucleic Acids Res. 2020;48(D1):D948\u201355.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2273_CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27\u201338.","journal-title":"Biometrika."},{"issue":"16","key":"2273_CR37","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409\u201319.","journal-title":"Stat Med"},{"issue":"6943","key":"2273_CR38","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1136\/bmj.308.6943.1552","volume":"308","author":"DG Altman","year":"1994","unstructured":"Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ. 1994;308(6943):1552.","journal-title":"BMJ"},{"key":"2273_CR39","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation; 2019. Available from: https:\/\/www.R-project.org\/."},{"issue":"7458","key":"2273_CR40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bmj.329.7458.168","volume":"329","author":"JJ Deeks","year":"2004","unstructured":"Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329(7458):168\u20139.","journal-title":"BMJ."},{"issue":"4","key":"2273_CR41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1445-5994.2011.02567.x","volume":"42","author":"MH Lee","year":"2012","unstructured":"Lee MH, Stocker SL, Anderson J, Phillips EJ, Nolan D, Williams KM, et al. Initiating allopurinol therapy: do we need to know the patient\u2019s human leucocyte antigen status? Intern Med J. 2012;42(4):411\u20136.","journal-title":"Intern Med J"},{"key":"2273_CR42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2016.00186","volume":"7","author":"C Sukasem","year":"2016","unstructured":"Sukasem C, Jantararoungtong T, Kuntawong P, Puangpetch A, Koomdee N, Satapornpong P, et al. HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand. Front Pharmacol. 2016;7:186.","journal-title":"Front Pharmacol"},{"key":"2273_CR43","doi-asserted-by":"crossref","unstructured":"Park HJ, Yun J, Kang DY, Park JW, Koh YI, Kim S, Kim SH, Nam YH, Jeong YY, Kim CW, Park HK, Kim SH, Kang HR, Jung JW. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. Drug Allergy Work Group of KAAACI. J Allergy Clin Immunol Pract. 2019;7(8):2739-49.e3. httsp:\/\/doi.org\/10.1016\/j.jaip.2019.05.047. Epub 2019 Jun 13.","DOI":"10.1016\/j.jaip.2019.05.047"},{"issue":"1","key":"2273_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2273_CR45","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/BF00577759","volume":"72","author":"JX de Vries","year":"1994","unstructured":"de Vries JX, Voss A, Ittensohn A, Walter-Sack I, L\u00f6ffler W, Landthaler R, et al. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. Clin Investig. 1994;72(12):1076\u201381.","journal-title":"Clin Investig"},{"issue":"9","key":"2273_CR46","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","volume":"51","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Barclay ML, O\u2019Donnell JL, Zhang M, Drake J, Frampton C, et al. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. Rheumatol Oxf Engl. 2012;51(9):1670\u20136.","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"2273_CR47","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","volume":"136","author":"CY Ng","year":"2016","unstructured":"Ng CY, Yeh Y-T, Wang C-W, Hung S-I, Yang C-H, Chang Y-C, et al. Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 2016;136(7):1373\u201381.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2273_CR48","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646\u201350.","journal-title":"J Rheumatol"},{"issue":"7","key":"2273_CR49","first-page":"2984","volume":"192","author":"J Yun","year":"2014","unstructured":"Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol Baltim Md 1950. 2014;192(7):2984\u201393.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"1","key":"2273_CR50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.161","volume":"99","author":"Y Saito","year":"2016","unstructured":"Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"2273_CR51","first-page":"396","volume":"25","author":"T Do","year":"2015","unstructured":"Do T, Tran T, Vu T, Tran Q, Nguyen T, Chu C, et al. Association between HLA*B5801 and allopurinol-induced severe cutaneous adverse drug reaction in Bachmai hospital. Tap Chi Hoc Phong. 2015;25:396\u2013400.","journal-title":"Tap Chi Hoc Phong"},{"issue":"2","key":"2273_CR52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1399-0039.2007.00982.x","volume":"71","author":"BK Hoa","year":"2008","unstructured":"Hoa BK, Hang NTL, Kashiwase K, Ohashi J, Lien LT, Horie T, et al. HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam. Tissue Antigens. 2008;71(2):127\u201334.","journal-title":"Tissue Antigens"},{"issue":"4","key":"2273_CR53","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaip.2018.11.039","volume":"7","author":"J-S Shim","year":"2019","unstructured":"Shim J-S, Yun J, Kim M-Y, Chung SJ, Oh JH, Kang D-Y, et al. The presence of HLA-B75, DR13 homozygosity, or DR14 additionally increases the risk of allopurinol-induced severe cutaneous adverse reactions in HLA-B*58:01 carriers. J Allergy Clin Immunol Pract. 2019;7(4):1261\u201370.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2273_CR54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","volume":"12","author":"R Somkrua","year":"2011","unstructured":"Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.","journal-title":"BMC Med Genet"},{"issue":"9","key":"2273_CR55","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/1756-185X.13143","volume":"20","author":"K-H Yu","year":"2017","unstructured":"Yu K-H, Yu C-Y, Fang Y-F. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. Int J Rheum Dis. 2017;20(9):1057\u201371.","journal-title":"Int J Rheum Dis"},{"issue":"24","key":"2273_CR56","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1002\/sim.2687","volume":"25","author":"G Heinze","year":"2006","unstructured":"Heinze G. A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med. 2006;25(24):4216\u201326.","journal-title":"Stat Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02273-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T18:03:30Z","timestamp":1723485810000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02273-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02273-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the University of Medicine and Pharmacy at Ho Chi Minh City (HEC\/IRB no. 198\/\u0110HYD-H\u0110). Oral and written informed consent was obtained for all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}